Seres Therapeutics (MCRB) Assets Average (2016 - 2025)
Historic Assets Average for Seres Therapeutics (MCRB) over the last 11 years, with Q3 2025 value amounting to $143.6 million.
- Seres Therapeutics' Assets Average fell 4259.97% to $143.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.6 million, marking a year-over-year decrease of 4259.97%. This contributed to the annual value of $249.2 million for FY2024, which is 2954.18% down from last year.
- As of Q3 2025, Seres Therapeutics' Assets Average stood at $143.6 million, which was down 4259.97% from $154.0 million recorded in Q2 2025.
- Over the past 5 years, Seres Therapeutics' Assets Average peaked at $387.0 million during Q3 2023, and registered a low of $143.6 million during Q3 2025.
- Its 5-year average for Assets Average is $290.3 million, with a median of $324.3 million in 2021.
- In the last 5 years, Seres Therapeutics' Assets Average soared by 17229.11% in 2021 and then plummeted by 5656.4% in 2025.
- Seres Therapeutics' Assets Average (Quarter) stood at $375.6 million in 2021, then fell by 12.05% to $330.3 million in 2022, then increased by 9.94% to $363.1 million in 2023, then plummeted by 56.14% to $159.3 million in 2024, then fell by 9.82% to $143.6 million in 2025.
- Its Assets Average stands at $143.6 million for Q3 2025, versus $154.0 million for Q2 2025 and $152.0 million for Q1 2025.